Literature DB >> 18189338

A rank-based sample size method for multiple outcomes in clinical trials.

Peng Huang1, Robert F Woolson, Peter C O'Brien.   

Abstract

O'Brien (Biometrics 1984; 40:1079-1087) introduced a rank-sum-type global statistical test to summarize treatment's effect on multiple outcomes and to determine whether a treatment is better than others. This paper presents a sample size computation method for clinical trial design with multiple primary outcomes, and O'Brien's test or its modified test (Biometrics 2005; 61:532-539) is used for the primary analysis. A new measure, the global treatment effect (GTE), is introduced to summarize treatment's efficacy from multiple primary outcomes. Computation of the GTE under various settings is provided. Sample size methods are presented based on prespecified GTE both when pilot data are available and when no pilot data are available. The optimal randomization ratio is given for both cases. We compare our sample size method with the Bonferroni adjustment for multiple tests. Since ranks are used in our derivation, sample size formulas derived here are invariant to any monotone transformation of the data and are robust to outliers and skewed distributions. When all outcomes are binary, we show how sample size is affected by the success probabilities of outcomes. Simulation shows that these sample size formulas provide good control of type I error and statistical power. An application to a Parkinson's disease clinical trial design is demonstrated. Splus codes to compute sample size and the test statistic are provided.

Entities:  

Mesh:

Year:  2008        PMID: 18189338      PMCID: PMC3163145          DOI: 10.1002/sim.3182

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  9 in total

1.  Power and sample size for ordered categorical data.

Authors:  N Rabbee; B A Coull; C Mehta; N Patel; P Senchaudhuri
Journal:  Stat Methods Med Res       Date:  2003-01       Impact factor: 3.021

2.  Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem.

Authors:  Peng Huang; Barbara C Tilley; Robert F Woolson; Stuart Lipsitz
Journal:  Biometrics       Date:  2005-06       Impact factor: 2.571

3.  Caution regarding the use of pilot studies to guide power calculations for study proposals.

Authors:  Helena Chmura Kraemer; Jim Mintz; Art Noda; Jared Tinklenberg; Jerome A Yesavage
Journal:  Arch Gen Psychiatry       Date:  2006-05

4.  Application of GEE procedures for sample size calculations in repeated measures experiments.

Authors:  J Rochon
Journal:  Stat Med       Date:  1998-07-30       Impact factor: 2.373

5.  Interpreting tests for efficacy in clinical trials with multiple endpoints.

Authors:  P C O'Brien; N L Geller
Journal:  Control Clin Trials       Date:  1997-06

6.  Probabilistic index: an intuitive non-parametric approach to measuring the size of treatment effects.

Authors:  Laura Acion; John J Peterson; Scott Temple; Stephan Arndt
Journal:  Stat Med       Date:  2006-02-28       Impact factor: 2.373

7.  Sample size calculations for ordered categorical data.

Authors:  J Whitehead
Journal:  Stat Med       Date:  1993-12-30       Impact factor: 2.373

8.  Procedures for comparing samples with multiple endpoints.

Authors:  P C O'Brien
Journal:  Biometrics       Date:  1984-12       Impact factor: 2.571

9.  Introduction to sample size determination and power analysis for clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1981-06
  9 in total
  14 in total

1.  Basal-like breast cancer displays distinct patterns of promoter methylation.

Authors:  Ji Shin Lee; Mary Jo Fackler; Jae Hyuk Lee; Chan Choi; Min Ho Park; Jung Han Yoon; Zhe Zhang; Saraswati Sukumar
Journal:  Cancer Biol Ther       Date:  2010-06-18       Impact factor: 4.742

2.  A Bayesian approach to joint analysis of multivariate longitudinal data and parametric accelerated failure time.

Authors:  Sheng Luo
Journal:  Stat Med       Date:  2013-09-06       Impact factor: 2.373

Review 3.  Establishing an evaluation mode with multiple primary outcomes based on combination of diseases and symptoms in TCM clinical trials.

Authors:  Jing Hu; Shuo Liu; Weihong Liu; Huina Zhang; Jing Chen; Hongcai Shang
Journal:  Ann Transl Med       Date:  2017-11

4.  Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial.

Authors:  W Poon; C Matula; P E Vos; D F Muresanu; N von Steinbüchel; K von Wild; V Hömberg; E Wang; T M C Lee; S Strilciuc; J C Vester
Journal:  Neurol Sci       Date:  2019-09-07       Impact factor: 3.307

5.  Added Value of Computer-aided CT Image Features for Early Lung Cancer Diagnosis with Small Pulmonary Nodules: A Matched Case-Control Study.

Authors:  Peng Huang; Seyoun Park; Rongkai Yan; Junghoon Lee; Linda C Chu; Cheng T Lin; Amira Hussien; Joshua Rathmell; Brett Thomas; Chen Chen; Russell Hales; David S Ettinger; Malcolm Brock; Ping Hu; Elliot K Fishman; Edward Gabrielson; Stephen Lam
Journal:  Radiology       Date:  2017-09-05       Impact factor: 11.105

6.  Using global statistical tests in long-term Parkinson's disease clinical trials.

Authors:  Peng Huang; Christopher G Goetz; Robert F Woolson; Barbara Tilley; Douglas Kerr; Yuko Palesch; Jordan Elm; Bernard Ravina; Kenneth J Bergmann; Karl Kieburtz
Journal:  Mov Disord       Date:  2009-09-15       Impact factor: 10.338

7.  Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial.

Authors:  Sheng Luo; Andrew B Lawson; Bo He; Jordan J Elm; Barbara C Tilley
Journal:  Stat Methods Med Res       Date:  2012-12-12       Impact factor: 3.021

8.  Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.

Authors:  Jordan J Elm
Journal:  Mov Disord       Date:  2012-10       Impact factor: 10.338

9.  Global rank tests for multiple, possibly censored, outcomes.

Authors:  Ritesh Ramchandani; David A Schoenfeld; Dianne M Finkelstein
Journal:  Biometrics       Date:  2016-01-26       Impact factor: 2.571

10.  Formulating appropriate statistical hypotheses for treatment comparison in clinical trial design and analysis.

Authors:  Peng Huang; Ai-hua Ou; Steven Piantadosi; Ming Tan
Journal:  Contemp Clin Trials       Date:  2014-10-13       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.